Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 31
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04725240 | Open-Label Study of Setmelanotide in Hypothalamic Obesity | ||
| NCT02896192 | Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity | ||
| NCT03287960 | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | ||
| NCT06046443 | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | ||
| NCT04963231 | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway | ||
| NCT02311673 | Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | ||
| NCT03651765 | Long Term Extension Trial of Setmelanotide | ||
| NCT02041195 | Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients | ||
| NCT06239064 | Early Genetic Identification of Obesity | ||
| NCT05183802 | An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) | ||
| NCT03013543 | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | ||
| NCT03262610 | Setmelanotide in a Single Patient With Partial Lipodystrophy | ||
| NCT06760546 | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | ||
| NCT05093634 | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | ||
| NCT06239116 | A Study of RM-718 in Healthy Subjects and in Patients With HO | ||
| NCT04966741 | Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity | ||
| NCT02431442 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers | ||
| NCT04348175 | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment | ||
| NCT06596135 | Open-Label Extension Study of Setmelanotide | ||
| NCT03479437 | The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry | ||
| NCT05194124 | Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | ||
| NCT01867437 | Effects of RM-493 on Energy Expenditure in Obese Individuals | ||
| NCT06420622 | INDIcators for Clarifying the bAckground of exTreme Obesity in childRen | ||
| NCT03746522 | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | ||
| NCT05774756 | A Trial of Setmelanotide in Acquired Hypothalamic Obesity | ||
| NCT03621007 | An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes | ||
| NCT01749137 | Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants | ||
| NCT05046132 | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants | ||
| NCT01849705 | Melanocortin 4 Receptor Mutations and Obesity-associated Diseases | ||
| NCT02849977 | Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers | ||
| NCT06772597 | A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome |
